Lexicon Pharmaceuticals (LXRX) to Release Earnings on Thursday

Lexicon Pharmaceuticals (NASDAQ:LXRX) is expected to be issuing its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 5, 2026 at 8:30 AM ET.

Lexicon Pharmaceuticals Stock Up 6.1%

Shares of NASDAQ:LXRX opened at $1.56 on Tuesday. Lexicon Pharmaceuticals has a fifty-two week low of $0.28 and a fifty-two week high of $1.83. The company has a quick ratio of 5.63, a current ratio of 5.64 and a debt-to-equity ratio of 0.47. The firm’s 50-day simple moving average is $1.33 and its 200-day simple moving average is $1.32. The company has a market cap of $567.01 million, a price-to-earnings ratio of -8.21 and a beta of 0.94.

Insider Transactions at Lexicon Pharmaceuticals

In other news, Director Raymond Debbane bought 100,000 shares of the stock in a transaction on Monday, February 23rd. The shares were bought at an average price of $1.47 per share, with a total value of $147,000.00. Following the completion of the acquisition, the director owned 1,904,186 shares of the company’s stock, valued at approximately $2,799,153.42. This trade represents a 5.54% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Invus Global Management, Llc bought 1,538,462 shares of the stock in a transaction on Monday, February 2nd. The shares were bought at an average price of $1.30 per share, for a total transaction of $2,000,000.60. Following the acquisition, the director owned 1,538,462 shares in the company, valued at $2,000,000.60. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders acquired 1,790,462 shares of company stock valued at $2,369,981. 13.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LXRX. Security National Bank of Sioux City Iowa IA acquired a new stake in Lexicon Pharmaceuticals during the fourth quarter worth about $31,000. Hudson Bay Capital Management LP purchased a new stake in shares of Lexicon Pharmaceuticals during the 2nd quarter worth about $26,000. EntryPoint Capital LLC acquired a new stake in Lexicon Pharmaceuticals during the 4th quarter worth approximately $39,000. Virtu Financial LLC purchased a new position in Lexicon Pharmaceuticals in the fourth quarter valued at approximately $42,000. Finally, CIBC Asset Management Inc purchased a new position in Lexicon Pharmaceuticals in the fourth quarter valued at approximately $45,000. Institutional investors and hedge funds own 74.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on LXRX shares. Wall Street Zen lowered Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a report on Thursday, January 22nd. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $3.23.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.